Esperion Therapeutics Inc (ESPR) Position Lifted by Schwab Charles Investment Management Inc.
Schwab Charles Investment Management Inc. increased its position in Esperion Therapeutics Inc (NASDAQ:ESPR) by 34.5% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 91,843 shares of the biopharmaceutical company’s stock after buying an additional 23,568 shares during the period. Schwab Charles Investment Management Inc.’s holdings in Esperion Therapeutics were worth $4,604,000 at the end of the most recent quarter.
Other institutional investors have also recently modified their holdings of the company. Tower Research Capital LLC TRC boosted its holdings in Esperion Therapeutics by 69,371.4% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,863 shares of the biopharmaceutical company’s stock worth $225,000 after buying an additional 4,856 shares during the period. SG Americas Securities LLC boosted its holdings in Esperion Therapeutics by 74.5% in the 2nd quarter. SG Americas Securities LLC now owns 7,008 shares of the biopharmaceutical company’s stock worth $324,000 after buying an additional 2,991 shares during the period. Voya Investment Management LLC boosted its holdings in Esperion Therapeutics by 12.7% in the 2nd quarter. Voya Investment Management LLC now owns 7,148 shares of the biopharmaceutical company’s stock worth $331,000 after buying an additional 806 shares during the period. State of Wisconsin Investment Board bought a new position in Esperion Therapeutics in the 2nd quarter worth $509,000. Finally, American International Group Inc. boosted its holdings in shares of Esperion Therapeutics by 21.6% during the 3rd quarter. American International Group Inc. now owns 11,257 shares of the biopharmaceutical company’s stock valued at $564,000 after purchasing an additional 2,001 shares during the last quarter. 92.24% of the stock is owned by institutional investors.
Shares of Esperion Therapeutics Inc (NASDAQ ESPR) opened at $68.50 on Thursday. The stock has a market cap of $1,760.00, a PE ratio of -9.99 and a beta of 2.73. Esperion Therapeutics Inc has a 1 year low of $10.71 and a 1 year high of $69.74.
In other news, Director Nicole Vitullo sold 9,326 shares of the company’s stock in a transaction dated Wednesday, December 6th. The shares were sold at an average price of $53.85, for a total transaction of $502,205.10. Following the sale, the director now directly owns 2,472 shares in the company, valued at approximately $133,117.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 32.50% of the stock is currently owned by corporate insiders.
Several research analysts have commented on ESPR shares. Chardan Capital increased their price objective on shares of Esperion Therapeutics from $20.00 to $75.00 and gave the company a “neutral” rating in a report on Wednesday, December 6th. Needham & Company LLC raised shares of Esperion Therapeutics from a “buy” rating to a “strong-buy” rating and increased their price objective for the company from $72.00 to $81.00 in a report on Thursday, December 14th. Northland Securities reissued a “buy” rating and set a $72.00 price objective on shares of Esperion Therapeutics in a report on Friday, November 10th. BidaskClub raised shares of Esperion Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, December 16th. Finally, Stifel Nicolaus reissued a “buy” rating and set a $70.00 price objective on shares of Esperion Therapeutics in a report on Wednesday, October 4th. Six analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. Esperion Therapeutics has an average rating of “Buy” and an average target price of $62.08.
Esperion Therapeutics Profile
Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.
Want to see what other hedge funds are holding ESPR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Esperion Therapeutics Inc (NASDAQ:ESPR).
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.